BR0013743A - Acido nucleico recombinante ou isolado ou seu fragmento funcional ou seu equivalente funcional, vetor, célula hospedeira, substancia proteinácea associada a apoptina recombinante ou isolada, anticorpo isolado ou sintético, uso de um ácido nucleico, composição farmacêutica, e, métodos para tratar um indivìduo abrigando uma doença, para detectar a presença de células cancerosas ou células propensas ao cancer em uma amostra de células, e para identificar um agente indutor de cancer putativo - Google Patents

Acido nucleico recombinante ou isolado ou seu fragmento funcional ou seu equivalente funcional, vetor, célula hospedeira, substancia proteinácea associada a apoptina recombinante ou isolada, anticorpo isolado ou sintético, uso de um ácido nucleico, composição farmacêutica, e, métodos para tratar um indivìduo abrigando uma doença, para detectar a presença de células cancerosas ou células propensas ao cancer em uma amostra de células, e para identificar um agente indutor de cancer putativo

Info

Publication number
BR0013743A
BR0013743A BR0013743-0A BR0013743A BR0013743A BR 0013743 A BR0013743 A BR 0013743A BR 0013743 A BR0013743 A BR 0013743A BR 0013743 A BR0013743 A BR 0013743A
Authority
BR
Brazil
Prior art keywords
isolated
recombinant
cells
nucleic acid
cancer
Prior art date
Application number
BR0013743-0A
Other languages
English (en)
Inventor
Mathieu Hubertus Mari Noteborn
Astrid Adriana Anna M Oorschot
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99202858A external-priority patent/EP1081226A1/en
Priority claimed from EP99203465A external-priority patent/EP1108785A1/en
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of BR0013743A publication Critical patent/BR0013743A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"áCIDO NUCLEICO RECOMBINANTE OU ISOLADO OU SEU FRAGMENTO FUNCIONAL OU SEU EQUIVALENTE FUNCIONAL, VETOR, CéLULA HOSPEDEIRA, SUBSTANCIA PROTEINáCEA ASSOCIADA A APOPTINA RECOMBINANTE OU ISOLADA, ANTICORPO ISOLADO OU SINTéTICO, USO DE UM áCIDO NUCLEICO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA TRATAR UM INDIVìDUO ABRIGANDO UMA DOENçA, PARA DETECTAR A PRESENçA DE CéLULAS CANCEROSAS OU CéLULAS PROPENSAS AO CANCER EM UMA AMOSTRA DE CéLULAS, E PARA IDENTIFICAR UM AGENTE INDUTOR DE CANCER PUTATIVO". A invenção refere-se ao campo da apoptose. A invenção proporciona novas possibilidades terapêuticas, por exemplo novas terapias combinatórias ou novos compostos terapêuticos que podem funcionar sozinhos, seq³encialmente à, ou juntamente com apoptina, especialmente naqueles casos nos quais p53 é (parcialmente) não-funcional.
BR0013743-0A 1999-09-02 2000-09-01 Acido nucleico recombinante ou isolado ou seu fragmento funcional ou seu equivalente funcional, vetor, célula hospedeira, substancia proteinácea associada a apoptina recombinante ou isolada, anticorpo isolado ou sintético, uso de um ácido nucleico, composição farmacêutica, e, métodos para tratar um indivìduo abrigando uma doença, para detectar a presença de células cancerosas ou células propensas ao cancer em uma amostra de células, e para identificar um agente indutor de cancer putativo BR0013743A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99202858A EP1081226A1 (en) 1999-09-02 1999-09-02 Apoptin-associating protein
EP99203465A EP1108785A1 (en) 1999-10-21 1999-10-21 Apoptin-associating protein
PCT/NL2000/000612 WO2001016165A2 (en) 1999-09-02 2000-09-01 Apoptin-associating protein

Publications (1)

Publication Number Publication Date
BR0013743A true BR0013743A (pt) 2005-01-11

Family

ID=26153361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013743-0A BR0013743A (pt) 1999-09-02 2000-09-01 Acido nucleico recombinante ou isolado ou seu fragmento funcional ou seu equivalente funcional, vetor, célula hospedeira, substancia proteinácea associada a apoptina recombinante ou isolada, anticorpo isolado ou sintético, uso de um ácido nucleico, composição farmacêutica, e, métodos para tratar um indivìduo abrigando uma doença, para detectar a presença de células cancerosas ou células propensas ao cancer em uma amostra de células, e para identificar um agente indutor de cancer putativo

Country Status (20)

Country Link
US (2) US7317096B1 (pt)
EP (1) EP1083224B1 (pt)
JP (1) JP2003510030A (pt)
CN (1) CN100513565C (pt)
AT (1) ATE347597T1 (pt)
AU (1) AU781127B2 (pt)
BR (1) BR0013743A (pt)
CA (1) CA2383784A1 (pt)
CY (1) CY1106355T1 (pt)
DE (1) DE60032201T2 (pt)
DK (1) DK1083224T3 (pt)
EA (1) EA005933B1 (pt)
ES (1) ES2277815T3 (pt)
HU (1) HUP0202688A2 (pt)
IL (2) IL148469A0 (pt)
NO (1) NO20021067L (pt)
NZ (1) NZ517740A (pt)
PL (1) PL204275B1 (pt)
PT (1) PT1083224E (pt)
WO (1) WO2001016165A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516152A (ja) * 1999-12-10 2003-05-13 レアト ベー．フェー． アポプチン会合タンパク質
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
WO2011100428A2 (en) * 2010-02-10 2011-08-18 The Uab Research Foundation Compositions for improving bone mass

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) * 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
DE69534492T2 (de) 1994-12-22 2006-06-14 Novartis Ag Nukleäre protein serin/threoninkinasen
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
CA2283299A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
CA2301401C (en) * 1997-08-12 2008-10-21 Leadd B.V. Determining the transforming capability of agents
EP0921192A1 (en) 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
EP0924296A3 (en) * 1997-12-03 2001-08-01 Leadd B.V. Methods and means for inducing apoptosis by interference in RNA processing
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US20030105315A1 (en) 1998-04-09 2003-06-05 Metagen Pharmaceuticals Gmbh Human nucleic acid sequences from ovarian tumor tissue
CA2327259A1 (en) * 1998-05-05 1999-11-11 Incyte Pharmaceuticals, Inc. Human transcriptional regulator molecules
EP1106691A1 (en) 1999-12-10 2001-06-13 Leadd B.V. Apoptin-associating protein
JP2003516152A (ja) 1999-12-10 2003-05-13 レアト ベー．フェー． アポプチン会合タンパク質
EP1111045A3 (en) 1999-12-10 2001-09-19 Leadd B.V. Apoptin-associating protein
WO2001053351A2 (en) 2000-01-17 2001-07-26 Leadd B.V. Apoptin bindendes protein
EP1138765A1 (en) 2000-03-27 2001-10-04 Leadd B.V. Apoptin-associating proteins AAP-5 and AAP-6

Also Published As

Publication number Publication date
US7767790B2 (en) 2010-08-03
NZ517740A (en) 2003-09-26
CN1387569A (zh) 2002-12-25
AU781127B2 (en) 2005-05-05
WO2001016165A3 (en) 2001-09-20
NO20021067D0 (no) 2002-03-04
US7317096B1 (en) 2008-01-08
DE60032201T2 (de) 2007-09-20
EA200200321A1 (ru) 2002-08-29
ATE347597T1 (de) 2006-12-15
JP2003510030A (ja) 2003-03-18
ES2277815T3 (es) 2007-08-01
HUP0202688A2 (en) 2002-12-28
EP1083224A3 (en) 2001-04-25
AU7324200A (en) 2001-03-26
CN100513565C (zh) 2009-07-15
CA2383784A1 (en) 2001-03-08
CY1106355T1 (el) 2011-10-12
NO20021067L (no) 2002-05-02
EA005933B1 (ru) 2005-08-25
US20080176231A1 (en) 2008-07-24
EP1083224B1 (en) 2006-12-06
DE60032201D1 (de) 2007-01-18
IL148469A0 (en) 2002-09-12
EP1083224A2 (en) 2001-03-14
PT1083224E (pt) 2007-03-30
PL354285A1 (en) 2003-12-29
PL204275B1 (pl) 2009-12-31
IL148469A (en) 2009-02-11
DK1083224T3 (da) 2007-04-10
WO2001016165A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
Munger et al. The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents BAD-induced programmed cell death in the absence of other viral proteins
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
Weiss et al. Enhanced heat shock protein 70 expression alters proteasomal degradation of IκB kinase in experimental acute respiratory distress syndrome
Stohrer et al. Oncotic pressure in solid tumors is elevated
Treutiger et al. High mobility group 1 B‐box mediates activation of human endothelium
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
Boeke et al. The minimal repression domain of MBD2b overlaps with the methyl-CpG-binding domain and binds directly to Sin3A
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
Wang et al. Obtusilactone A and (−)‐sesamin induce apoptosis in human lung cancer cells by inhibiting mitochondrial Lon protease and activating DNA damage checkpoints
BRPI0408928A (pt) métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
Kothny-Wilkes et al. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand-and CD95-induced apoptosis but not from ultraviolet radiation-induced apoptosis
BR9916642A (pt) Método e composição de substrato para uso no isolamento de irritantes cutâneos
BR9808863A (pt) Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama
HUP0301740A2 (hu) Emlőrák kezelésére és diagnosztizálására szolgáló készítmények és eljárások
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
BR112023015191A2 (pt) Agentes terapêuticos e de diagnóstico e usos dos mesmos
Zhou et al. Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
Fattman et al. p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
BR9915071A (pt) Utilização de uma proteìna ompa de enterobactéria ou de um de seus fragmentos
WO2001002556A3 (de) Mittel zur diagnose, prognose und therapie maligner erkrankungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 11, 13, 10, 18 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.